Renalytix plc (RNLXY) stock
RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)
Close on Oct 19, 2026Market cap $375.75MP/E –Yield –
Earnings
Renalytix's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2024
$500.00K
EPS, Q3 FY2024
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Renalytix's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2025ended Sep 30, 2024 | Oct 1, 2024during market hours | – | – | – | Release |
| Q3 FY2024ended Mar 31, 2024 | May 15, 2024before the open | $500.00K | – | – | Release |
| Q2 FY2024ended Dec 31, 2023 | Feb 15, 2024before the open | $700.00K | – | -$0.09 | Release |
| Q1 FY2024ended Sep 30, 2023 | Nov 14, 2023before the open | $500.00K | – | – | Release |
| Q4 FY2023ended Jun 30, 2023 | Sep 28, 2023before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Renalytix has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Renalytix puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Renalytix filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Results
- Results
- Update
- Update
- Update
- Update
- Results
- News
- Update
- Update
- Update
See a number that looks wrong?